Page last updated: 2024-12-11
actisomide
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
SC 36602: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 6917898 |
| CHEMBL ID | 561826 |
| SCHEMBL ID | 121854 |
| MeSH ID | M0147362 |
Synonyms (27)
| Synonym |
|---|
| sc-36602 |
| actisomide |
| 96914-39-5 |
| D02762 |
| actisomide (usan/inn) |
| sc 36602 |
| CHEMBL561826 |
| (4r,4ar)-4-[2-[di(propan-2-yl)amino]ethyl]-1-methyl-4-phenyl-5,6,7,8-tetrahydro-4ah-pyrido[1,2-c]pyrimidin-3-one |
| ijq29n87nr , |
| actisomida |
| actisomidum [inn-latin] |
| unii-ijq29n87nr |
| actisomida [inn-spanish] |
| actisomide [usan:inn] |
| 3h-pyrido(1,2-c)pyrimidin-3-one, 4-(2-(bis(1-methylethyl)amino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-, cis-(+-)- |
| actisomidum |
| (+-)-cis-4-(2-(diisopropylamino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-3h-pyrido(1,2-c)pyrimidin-3-one |
| actisomide [inn] |
| actisomide [usan] |
| 3h-pyrido(1,2-c)pyrimidin-3-one, 4-(2-(bis(1-methylethyl)amino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-, cis-(+/-)- |
| (+/-)-cis-4-(2-(diisopropylamino)ethyl)-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-3h-pyrido(1,2-c)pyrimidin-3-one |
| SCHEMBL121854 |
| (4r)-4-[2-[di(propan-2-yl)amino]ethyl]-1-methyl-4-phenyl-5,6,7,8-tetrahydro-4ah-pyrido[2,1-f]pyrimidin-3-one |
| Q15633951 |
| (4r,4ar)-4-(2-(diisopropylamino)ethyl)-1-methyl-4-phenyl-4,4a,5,6,7,8-hexahydro-3h-pyrido[1,2-c]pyrimidin-3-one |
| DTXSID001026019 |
| 3h-pyrido[1,2-c]pyrimidin-3-one, 4-[2-[bis(1-methylethyl)amino]ethyl]-4,4a,5,6,7,8-hexahydro-1-methyl-4-phenyl-, (4r,4ar)-rel- |
Research Excerpts
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|---|---|
| "1 mg/kg) were below the assay's limit of detection and were not included in the pharmacokinetic analysis." | ( Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. Dean, RR; Destache, CJ; Hilleman, DE; Malesker, MA; Mohiuddin, SM; Sketch, MH; Stoysich, A, 1991) | 0.54 |
| " The terminal half-life of actisomide was similar (1." | ( Pharmacokinetics of a novel antiarrhythmic drug, actisomide. Anderson, S; Cook, CS; Karim, A; Rozek, LF; Schoenhard, GL; Stolzenbach, J, 1993) | 0.84 |
Dosage Studied
| Excerpt | Relevance | Reference |
|---|---|---|
| " Mild subjective adverse effects (dizziness, taste perversion, and circumoral paresthesia) which did not necessitate discontinuing the infusion occurred in the highest dosage group." | ( Pharmacokinetic and tolerance evaluation of actisomide, a new antiarrhythmic agent, in healthy volunteers. Dean, RR; Destache, CJ; Hilleman, DE; Malesker, MA; Mohiuddin, SM; Sketch, MH; Stoysich, A, 1991) | 0.54 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 3 (60.00) | 18.7374 |
| 1990's | 2 (40.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.31
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.31) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 1 (16.67%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||